Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Episodic hyperCKaemia may be a feature of α-methylacyl-coenzyme A racemase deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  • EUROMAC Consortium
View graph of relations

BACKGROUND: International patient registries are of particular importance for rare disorders, as they may contribute to overcome the lack of knowledge derived from low number of patients and limited awareness of these diseases, and help to learn more about their geographical or population-based specificities, which is relevant for research purposes and for promoting better standards of care and diagnosis. Our objective was to create and implement a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) and to disseminate the knowledge of these disorders.

RESULTS: Teams from nine different countries (United Kingdom, Spain, Italy, France, Germany, Denmark, Greece, Turkey and USA) created a consortium that developed the first European registry dedicated to rare muscle glycogenoses. A work plan was implemented to design the database and platform that constitute the registry, by choosing clinical, genetics and molecular variables of interest, based on experience gained from previous national registries for similar metabolic disorders. Among dissemination activities, several teaching events were organized in different countries, especially those where the consortium considered the awareness of these diseases needs to be promoted among health professionals and patients.

CONCLUSION: EUROMAC represents a step forward in the knowledge of those disorders to which it is dedicated, and will have relevant clinical outcomes at the diagnostic, epidemiological, clinical and research level.

Original languageEnglish
Article number187
JournalOrphanet Journal of Rare Diseases
Volume15
Issue number1
Pages (from-to)187
ISSN1750-1172
DOIs
Publication statusPublished - 15 Oct 2020

    Research areas

  • Glycogen storage disease, International registry, McArdle disease, Metabolic diseases, Myopathy, Rare diseases

ID: 61072032